Cabaletta Bio, Inc.

What they do

Cabaletta discovers and develops engineered T cell therapies intended to deliver deep and durable, potentially curative, responses with one-time administration for autoimmune diseases. Its CABA platform centers on the CARTA approach, and its lead candidate, resecabtagene autoleucel (rese-cel), is a fully human CD19-CAR T construct designed to transiently and deeply deplete B cells so healthy transitional and naive B cells can repopulate. Rese-cel is being evaluated across the RESET clinical program in myositis, lupus, systemic sclerosis and generalized myasthenia gravis, using both standard preconditioning and PC-free regimens. Manufacturing is handled by third-party CDMOs, including Minaris, Lonza, Cellares and ElevateBio.

Revenue drivers

• Rese-cel in myositis (registrational) — Lead value driver; the registrational 17-patient DM and ASyS cohort is on track for mid-2027 data to support a first BLA submission in 2H27. Cabaletta has not reported any product revenue.
• Rese-cel in systemic sclerosis (planned registrational) — Registrational RESET-SSc enrollment of approximately 25 patients with SSc-associated interstitial lung disease is anticipated to initiate in 4Q26.
• Rese-cel PC-free approach across indications — The PC-free regimen is being incorporated into RESET-MG based on emerging insights from PC-free RESET-SLE and RESET-PV cohorts and previously reported Phase 1/2 data.
• Automated manufacturing via Cellares Cell Shuttle — An IND cleared in January 2026 for rese-cel manufactured on the Cellares Cell Shuttle, which the company says offers potential scalability to thousands of patients per year with minimal capital investment.

Recent performance

The company is pre-revenue and reported no product sales; annual net loss widened from $46.3M in 2021 to $167.9M in 2025, with operating cash use of $131.1M in 2025. At June 30, 2026, total assets were $256.7M, total liabilities $46.1M, shareholder equity $210.6M, and cash and equivalents $225.1M. At EULAR 2026, Cabaletta presented data from 52 evaluable autoimmune disease patients with myositis (17), lupus (20) and systemic sclerosis (15), including the first juvenile dermatomyositis patient and the first two lupus patients treated with PC-free rese-cel. It reported that 80% (8/10) of evaluable adult DM and ASyS patients would have met the registrational cohort's primary endpoint, with all DM responders maintaining responses through up to 1.5 years. Across all 17 RESET-Myositis Phase 1/2 patients reported at EULAR 2026, 100% had no or Grade 1 (fever) CRS and none experienced ICANS.

Strategy

Cabaletta is prioritizing registrational execution: reporting registrational RESET-Myositis data in mid-2027 toward a 2H27 BLA submission for rese-cel. The planned BLA would include the registrational cohort and juvenile cohort data, which may support potential FDA Priority Review Voucher eligibility. The company is expanding the PC-free approach, incorporating it into RESET-MG based on emerging PC-free RESET-SLE and RESET-PV insights, and initiating registrational RESET-SSc enrollment in approximately 25 SSc-ILD patients in 4Q26. It is also pursuing an expanded outpatient dosing option and adding ElevateBio as a second CDMO for clinical and commercial manufacturing.

Risks

• Going concern and funding need — The 10-K states conditions raise substantial doubt about the ability to continue as a going concern, and without additional funding beyond the current cash position enabling operations into Q4 2026, programs may be delayed, reduced or discontinued.
• CDMO dependence — Manufacturing relies on Minaris, Lonza and Cellares, and reduced, delayed or limited capacity at any of these partners could adversely impact supply for and enrollment in the RESET trials.
• Licensed IP dependence — The company relies on intellectual property licensed from Nanjing IASO Biotherapeutics, and termination of that license would result in loss of significant rights and a material adverse effect on the business.
• Early clinical development — The 10-K states the company is early in development and has not completed any clinical trials, so if it cannot advance product candidates through development and obtain regulatory approval, the business will be materially harmed.

Outlook

Management says registrational RESET-Myositis data are on track for mid-2027 to support a first BLA submission in 2H27, with the juvenile myositis Phase 1/2 data expected to be submitted with the BLA to support potential Priority Review Voucher eligibility. Registrational RESET-SSc enrollment in approximately 25 SSc-associated interstitial lung disease patients is anticipated to initiate in 4Q26. The company also expects to expand the outpatient dosing option for rese-cel across the RESET program and to incorporate the PC-free approach in RESET-MG. Durability data from the no-preconditioning SLE, LN and PV patients, as well as patients treated with rese-cel manufactured by the Cellares Cell Shuttle, are expected in the second half of 2026.